May 11, 2021 - GATINEAU, QC - Competition Bureau
Through its participation in the Multilateral Pharmaceutical Merger Task Force, the Competition Bureau, with its counterparts in the U.S., the European Union and the U.K., is reviewing its approach to the analysis of pharmaceutical mergers.
The task force is seeking input from stakeholders to inform its review of a variety of issues related to mergers in the pharmaceutical industry, including potential new or refreshed theories of harm, the evaluation of the effects of a merger on innovation and potential remedies to resolve competition concerns.
The task force encourages stakeholders, including health policy experts, economists, attorneys, scientists, health care practitioners, academics, and consumers to share ideas that will lead to the development of future enforcement and policy efforts.
The U.S. Federal Trade Commission, will collect submissions on behalf of the task force. Interested parties can review the consultation questions and provide written comments to the U.S. FTC by following the instructions in its public request for comment.
